What is Abbott Labs's earnings per share (EPS)?

Abbott Labs (ABT) reported diluted earnings per share of $3.72 for fiscal year 2025. This represents a -51.3% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Abbott Labs Financials

ABT

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Abbott Labs (ABT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 19 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 56/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Abbott Labs has an operating margin of 18.2%, meaning the company retains $18 of operating profit per $100 of revenue. This results in a moderate score of 63/100, indicating healthy but not exceptional operating efficiency. This is up from 16.3% the prior year.

Growth

Abbott Labs's revenue grew 5.7% year-over-year to $44.3B, a solid pace of expansion. This earns a growth score of 43/100.

Leverage

Abbott Labs carries a low D/E ratio of 0.19, meaning only $0.19 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 98/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

Abbott Labs's current ratio of 1.58 means current assets barely cover short-term liabilities. This tight liquidity results in a low score of 27/100, which could limit financial flexibility.

Cash Flow

Abbott Labs converts 16.7% of revenue into free cash flow ($7.4B). This strong cash generation earns a score of 67/100.

Returns

Abbott Labs's ROE of 12.5% shows moderate profitability relative to equity, earning a score of 39/100. This is down from 28.1% the prior year.

Altman Z-Score Safe

4.84

Abbott Labs scores 4.84, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($177.9B) relative to total liabilities ($34.6B). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Piotroski F-Score Neutral

5/9

Abbott Labs passes 5 of 9 financial strength tests. 3 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Cash-Backed

1.47x

For every $1 of reported earnings, Abbott Labs generates $1.47 in operating cash flow ($9.6B OCF vs $6.5B net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage Safe

16.3x

Abbott Labs earns $16.3 in operating income for every $1 of interest expense ($8.1B vs $493.0M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$44.3B

YoY+5.7%

5Y CAGR+5.1%

10Y CAGR+8.1%

Abbott Labs generated $44.3B in revenue in fiscal year 2025. This represents an increase of 5.7% from the prior year.

EBITDA

$11.2B

YoY+11.2%

5Y CAGR+5.2%

10Y CAGR+9.9%

Abbott Labs's EBITDA was $11.2B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 11.2% from the prior year.

Net Income

$6.5B

YoY-51.3%

5Y CAGR+7.7%

10Y CAGR+4.0%

Abbott Labs reported $6.5B in net income in fiscal year 2025. This represents a decrease of 51.3% from the prior year.

EPS (Diluted)

$3.72

YoY-51.3%

5Y CAGR+8.3%

10Y CAGR+2.5%

Abbott Labs earned $3.72 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 51.3% from the prior year.

Cash & Balance Sheet

Free Cash Flow

$7.4B

YoY+16.4%

5Y CAGR+5.3%

10Y CAGR+14.8%

Abbott Labs generated $7.4B in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 16.4% from the prior year.

Cash & Debt

$8.5B

YoY+11.9%

5Y CAGR+4.5%

10Y CAGR+5.5%

Abbott Labs held $8.5B in cash against $9.9B in long-term debt as of fiscal year 2025.

Dividends Per Share

$2.40

YoY+7.1%

Abbott Labs paid $2.40 per share in dividends in fiscal year 2025. This represents an increase of 7.1% from the prior year.

Shares Outstanding

1.74B

YoY+0.2%

5Y CAGR-0.4%

10Y CAGR+1.7%

Abbott Labs had 1.74B shares outstanding in fiscal year 2025. This represents an increase of 0.2% from the prior year.

Margins & Returns

Gross Margin

56.4%

YoY+1.0pp

5Y CAGR-0.2pp

10Y CAGR-0.7pp

Abbott Labs's gross margin was 56.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 1.0 percentage points from the prior year.

Operating Margin

18.2%

YoY+1.9pp

5Y CAGR+2.7pp

10Y CAGR+4.1pp

Abbott Labs's operating margin was 18.2% in fiscal year 2025, reflecting core business profitability. This is up 1.9 percentage points from the prior year.

Net Margin

14.7%

YoY-17.2pp

5Y CAGR+1.7pp

10Y CAGR-7.0pp

Abbott Labs's net profit margin was 14.7% in fiscal year 2025, showing the share of revenue converted to profit. This is down 17.2 percentage points from the prior year.

Return on Equity

12.5%

YoY-15.6pp

5Y CAGR-1.2pp

10Y CAGR-8.3pp

Abbott Labs's ROE was 12.5% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 15.6 percentage points from the prior year.

Capital Allocation

R&D Spending

$2.9B

YoY+3.4%

5Y CAGR+4.0%

10Y CAGR+7.7%

Abbott Labs invested $2.9B in research and development in fiscal year 2025. This represents an increase of 3.4% from the prior year.

Share Buybacks

$893.0M

YoY-31.0%

5Y CAGR+17.2%

10Y CAGR-8.8%

Abbott Labs spent $893.0M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 31.0% from the prior year.

Capital Expenditures

$2.2B

YoY-1.6%

5Y CAGR-0.1%

10Y CAGR+6.9%

Abbott Labs invested $2.2B in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 1.6% from the prior year.

ABT Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$44.3B+5.7%	$42.0B+4.6%	$40.1B-8.1%	$43.7B+1.3%	$43.1B+24.5%	$34.6B
Cost of Revenue	$19.3B+3.3%	$18.7B+4.1%	$18.0B-6.1%	$19.1B+3.3%	$18.5B+23.6%	$15.0B
Gross Profit	$25.0B+7.6%	$23.2B+5.0%	$22.1B-9.7%	$24.5B-0.1%	$24.5B+25.2%	$19.6B
R&D Expenses	$2.9B+3.4%	$2.8B+3.8%	$2.7B-5.1%	$2.9B+5.3%	$2.7B+13.3%	$2.4B
SG&A Expenses	$12.3B+5.4%	$11.7B+6.8%	$10.9B-2.7%	$11.2B-0.7%	$11.3B+16.8%	$9.7B
Operating Income	$8.1B+18.0%	$6.8B+5.4%	$6.5B-22.5%	$8.4B-0.7%	$8.4B+57.3%	$5.4B
Interest Expense	$493.0M-11.8%	$559.0M-12.2%	$637.0M+14.2%	$558.0M+4.7%	$533.0M-2.4%	$546.0M
Income Tax	$1.9B+130.4%	-$6.4B-779.0%	$941.0M-31.5%	$1.4B+20.4%	$1.1B+129.4%	$497.0M
Net Income	$6.5B-51.3%	$13.4B+134.2%	$5.7B-17.5%	$6.9B-2.0%	$7.1B+57.3%	$4.5B
EPS (Diluted)	$3.72-51.3%	$7.64+134.4%	$3.26-16.6%	$3.91-0.8%	$3.94+57.6%	$2.50

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	$11.5B+0.8%	$11.4B+2.0%	$11.1B+7.6%	$10.4B-5.6%	$11.0B+3.2%	$10.6B+2.5%	$10.4B+4.1%	$10.0B
Cost of Revenue	$4.9B-3.0%	$5.1B+4.6%	$4.9B+8.6%	$4.5B-9.6%	$4.9B+5.2%	$4.7B+2.1%	$4.6B+3.1%	$4.5B
Gross Profit	$6.5B+3.9%	$6.3B+0.1%	$6.3B+6.8%	$5.9B-2.4%	$6.0B+1.6%	$5.9B+2.8%	$5.8B+5.0%	$5.5B
R&D Expenses	$735.0M-4.0%	$766.0M+5.7%	$725.0M+1.3%	$716.0M-4.4%	$749.0M+5.0%	$713.0M+2.1%	$698.0M+2.0%	$684.0M
SG&A Expenses	$3.1B+2.6%	$3.1B-1.3%	$3.1B+1.0%	$3.1B+5.3%	$2.9B+0.4%	$2.9B-1.4%	$2.9B-0.8%	$3.0B
Operating Income	$2.3B+9.4%	$2.1B+0.2%	$2.1B+21.2%	$1.7B-11.4%	$1.9B+2.8%	$1.9B+11.4%	$1.7B+20.4%	$1.4B
Interest Expense	$120.0M-0.8%	$121.0M0.0%	$121.0M-7.6%	$131.0M-3.7%	$136.0M-4.2%	$142.0M+1.4%	$140.0M-0.7%	$141.0M
Income Tax	$582.0M+8.6%	$536.0M+44.5%	$371.0M-18.1%	$453.0M+106.3%	-$7.2B-2548.6%	$294.0M-3.6%	$305.0M+44.5%	$211.0M
Net Income	$1.8B+8.0%	$1.6B-7.6%	$1.8B+34.3%	$1.3B-85.6%	$9.2B+460.7%	$1.6B+26.4%	$1.3B+6.3%	$1.2B
EPS (Diluted)	N/A	$0.94-6.9%	$1.01+32.9%	$0.76	N/A	$0.94+27.0%	$0.74+5.7%	$0.70

ABT Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$86.7B+6.5%	$81.4B+11.2%	$73.2B-1.6%	$74.4B-1.0%	$75.2B+3.6%	$72.5B
Current Assets	$26.0B+9.9%	$23.7B+4.3%	$22.7B-10.1%	$25.2B+4.1%	$24.2B+18.6%	$20.4B
Cash & Equivalents	$8.5B+11.9%	$7.6B+10.4%	$6.9B-30.2%	$9.9B+0.8%	$9.8B+43.3%	$6.8B
Inventory	$6.5B+4.7%	$6.2B-5.7%	$6.6B+6.4%	$6.2B+19.7%	$5.2B+2.9%	$5.0B
Accounts Receivable	$7.9B+14.5%	$6.9B+5.5%	$6.6B+5.6%	$6.2B-4.1%	$6.5B+1.1%	$6.4B
Goodwill	$24.0B+4.0%	$23.1B-2.4%	$23.7B+3.9%	$22.8B-1.9%	$23.2B-2.2%	$23.7B
Total Liabilities	$34.6B+2.5%	$33.8B-2.5%	$34.6B-8.3%	$37.8B-4.2%	$39.4B-0.9%	$39.8B
Current Liabilities	$16.5B+16.5%	$14.2B+2.3%	$13.8B-10.6%	$15.5B+18.2%	$13.1B+10.1%	$11.9B
Long-Term Debt	$9.9B-21.6%	$12.6B-7.2%	$13.6B-6.4%	$14.5B-16.0%	$17.3B-6.6%	$18.5B
Total Equity	$52.1B+9.4%	$47.7B+23.5%	$38.6B+5.2%	$36.7B+2.5%	$35.8B+9.2%	$32.8B
Retained Earnings	$49.8B+5.3%	$47.3B+25.8%	$37.6B+6.5%	$35.3B+11.8%	$31.5B+14.1%	$27.6B

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$86.7B+3.0%	$84.2B+0.2%	$84.0B+3.1%	$81.4B0.0%	$81.4B+9.5%	$74.4B+1.8%	$73.0B+0.8%	$72.5B
Current Assets	$26.0B+4.7%	$24.8B+1.5%	$24.5B+5.7%	$23.2B-2.1%	$23.7B-0.6%	$23.8B+3.0%	$23.1B+3.3%	$22.4B
Cash & Equivalents	$8.5B+13.5%	$7.5B+8.1%	$7.0B+6.4%	$6.5B-14.2%	$7.6B+0.8%	$7.6B+8.2%	$7.0B+11.2%	$6.3B
Inventory	$6.5B-3.3%	$6.7B-3.5%	$7.0B+4.7%	$6.6B+7.2%	$6.2B-9.1%	$6.8B0.0%	$6.8B-0.2%	$6.8B
Accounts Receivable	$7.9B-2.6%	$8.1B+2.1%	$8.0B+8.8%	$7.3B+5.8%	$6.9B-1.8%	$7.1B+2.9%	$6.9B+3.8%	$6.6B
Goodwill	$24.0B+0.3%	$24.0B+0.1%	$24.0B+2.5%	$23.4B+1.1%	$23.1B-2.3%	$23.7B+1.5%	$23.3B-0.3%	$23.4B
Total Liabilities	$34.6B+4.1%	$33.2B-0.6%	$33.4B+2.4%	$32.6B-3.3%	$33.8B-2.3%	$34.6B+2.6%	$33.7B+0.1%	$33.7B
Current Liabilities	$16.5B+13.1%	$14.6B+8.5%	$13.4B+3.3%	$13.0B-8.1%	$14.2B-5.0%	$14.9B+8.3%	$13.8B-1.9%	$14.0B
Long-Term Debt	$9.9B-14.7%	$11.6B-10.3%	$12.9B+1.5%	$12.7B+0.9%	$12.6B-1.6%	$12.8B-2.4%	$13.1B+4.5%	$12.6B
Total Equity	$52.1B+2.3%	$51.0B+0.8%	$50.6B+3.6%	$48.8B+2.4%	$47.7B+19.8%	$39.8B+1.2%	$39.3B+1.3%	$38.8B
Retained Earnings	$49.8B+1.4%	$49.1B+1.3%	$48.5B+1.6%	$47.7B+1.0%	$47.3B+21.0%	$39.1B+1.8%	$38.4B+0.9%	$38.0B

ABT Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$9.6B+11.8%	$8.6B+17.9%	$7.3B-24.2%	$9.6B-9.0%	$10.5B+33.3%	$7.9B
Capital Expenditures	$2.2B-1.6%	$2.2B+0.2%	$2.2B+23.9%	$1.8B-5.7%	$1.9B-13.4%	$2.2B
Free Cash Flow	$7.4B+16.4%	$6.4B+25.5%	$5.1B-35.2%	$7.8B-9.8%	$8.6B+51.1%	$5.7B
Investing Cash Flow	-$2.4B-3.6%	-$2.3B+25.4%	-$3.1B-80.1%	-$1.7B+13.3%	-$2.0B+9.3%	-$2.2B
Financing Cash Flow	-$6.3B-16.7%	-$5.4B+23.8%	-$7.1B+7.1%	-$7.6B-39.0%	-$5.5B-97.7%	-$2.8B
Dividends Paid	$4.1B+7.3%	$3.8B+7.9%	$3.6B+7.5%	$3.3B+3.3%	$3.2B+25.1%	$2.6B
Share Buybacks	$893.0M-31.0%	$1.3B+5.5%	$1.2B-67.7%	$3.8B+65.1%	$2.3B+470.5%	$403.0M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	$3.3B+18.9%	$2.8B+36.2%	$2.0B+44.5%	$1.4B-50.6%	$2.9B+6.0%	$2.7B+38.0%	$2.0B+91.2%	$1.0B
Capital Expenditures	$689.0M+38.9%	$496.0M-1.2%	$502.0M+3.7%	$484.0M-32.8%	$720.0M+29.5%	$556.0M+4.3%	$533.0M+33.9%	$398.0M
Free Cash Flow	$2.6B+14.6%	$2.3B+48.3%	$1.5B+65.6%	$933.0M-56.6%	$2.1B0.0%	$2.1B+50.6%	$1.4B+127.6%	$627.0M
Investing Cash Flow	-$913.0M-99.8%	-$457.0M+21.5%	-$582.0M-23.8%	-$470.0M+45.7%	-$866.0M-45.8%	-$594.0M-31.1%	-$453.0M-6.6%	-$425.0M
Financing Cash Flow	-$1.4B+20.6%	-$1.8B-60.4%	-$1.1B+46.6%	-$2.1B-10.4%	-$1.9B-18.1%	-$1.6B-99.2%	-$791.0M+32.7%	-$1.2B
Dividends Paid	$1.0B-0.1%	$1.0B+0.2%	$1.0B+0.3%	$1.0B+7.1%	$958.0M-0.2%	$960.0M-0.1%	$961.0M+0.4%	$957.0M
Share Buybacks	$302.0M-1.0%	$305.0M+4983.3%	$6.0M-97.9%	$280.0M-11.1%	$315.0M-58.1%	$751.0M+24933.3%	$3.0M-98.7%	$226.0M

ABT Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	56.4%+1.0pp	55.4%+0.2pp	55.2%-1.0pp	56.1%-0.8pp	57.0%+0.3pp	56.6%
Operating Margin	18.2%+1.9pp	16.3%+0.1pp	16.2%-3.0pp	19.2%-0.4pp	19.6%+4.1pp	15.5%
Net Margin	14.7%-17.2pp	31.9%+17.7pp	14.3%-1.6pp	15.9%-0.5pp	16.4%+3.4pp	13.0%
Return on Equity	12.5%-15.6pp	28.1%+13.3pp	14.8%-4.1pp	18.9%-0.9pp	19.8%+6.0pp	13.7%
Return on Assets	7.5%-8.9pp	16.5%+8.6pp	7.8%-1.5pp	9.3%-0.1pp	9.4%+3.2pp	6.2%
Current Ratio	1.58-0.1	1.67+0.0	1.640.0	1.63-0.2	1.85+0.1	1.72
Debt-to-Equity	0.19-0.1	0.26-0.1	0.35-0.0	0.40-0.1	0.48-0.1	0.57
FCF Margin	16.7%+1.5pp	15.1%+2.5pp	12.6%-5.3pp	17.9%-2.2pp	20.1%+3.5pp	16.5%

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	57.0%+1.7pp	55.4%-1.1pp	56.4%-0.4pp	56.9%+1.9pp	55.0%-0.9pp	55.8%+0.2pp	55.6%+0.4pp	55.2%
Operating Margin	19.6%+1.5pp	18.1%-0.3pp	18.4%+2.1pp	16.3%-1.1pp	17.4%-0.1pp	17.5%+1.4pp	16.1%+2.2pp	13.9%
Net Margin	15.5%+1.0pp	14.5%-1.5pp	16.0%+3.2pp	12.8%-71.3pp	84.1%+68.6pp	15.5%+2.9pp	12.6%+0.3pp	12.3%
Return on Equity	3.4%+0.2pp	3.2%-0.3pp	3.5%+0.8pp	2.7%-16.6pp	19.4%+15.2pp	4.1%+0.8pp	3.3%+0.1pp	3.2%
Return on Assets	2.1%+0.1pp	1.9%-0.2pp	2.1%+0.5pp	1.6%-9.7pp	11.3%+9.1pp	2.2%+0.4pp	1.8%+0.1pp	1.7%
Current Ratio	1.58-0.1	1.70-0.1	1.82+0.0	1.78+0.1	1.67+0.1	1.60-0.1	1.68+0.1	1.60
Debt-to-Equity	0.19-0.0	0.23-0.0	0.260.0	0.260.0	0.26-0.1	0.32-0.0	0.33+0.0	0.32
FCF Margin	22.9%+2.8pp	20.2%+6.3pp	13.9%+4.9pp	9.0%-10.6pp	19.6%-0.6pp	20.2%+6.5pp	13.8%+7.5pp	6.3%

Similar Companies

Boston Scien Cp BSX

$92.1B

Stryker Corp SYK

$126.2B

Medtronic MDT

$110.5B

Edwards Lifesciences Corp EW

$46.8B

Smith & Nephew SNN

$13.6B

Frequently Asked Questions

What is Abbott Labs's annual revenue?

Abbott Labs (ABT) reported $44.3B in total revenue for fiscal year 2025. This represents a 5.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Abbott Labs's revenue growing?

Abbott Labs (ABT) revenue grew by 5.7% year-over-year, from $42.0B to $44.3B in fiscal year 2025.

Is Abbott Labs profitable?

Yes, Abbott Labs (ABT) reported a net income of $6.5B in fiscal year 2025, with a net profit margin of 14.7%.

What is Abbott Labs's EBITDA?

Abbott Labs (ABT) had EBITDA of $11.2B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Abbott Labs have?

As of fiscal year 2025, Abbott Labs (ABT) had $8.5B in cash and equivalents against $9.9B in long-term debt.

What is Abbott Labs's gross margin?

Abbott Labs (ABT) had a gross margin of 56.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Abbott Labs's operating margin?

Abbott Labs (ABT) had an operating margin of 18.2% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Abbott Labs's net profit margin?

Abbott Labs (ABT) had a net profit margin of 14.7% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Does Abbott Labs pay dividends?

Yes, Abbott Labs (ABT) paid $2.40 per share in dividends during fiscal year 2025.

What is Abbott Labs's return on equity (ROE)?

Abbott Labs (ABT) has a return on equity of 12.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Abbott Labs's free cash flow?

Abbott Labs (ABT) generated $7.4B in free cash flow during fiscal year 2025. This represents a 16.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Abbott Labs's operating cash flow?

Abbott Labs (ABT) generated $9.6B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Abbott Labs's total assets?

Abbott Labs (ABT) had $86.7B in total assets as of fiscal year 2025, including both current and long-term assets.

What are Abbott Labs's capital expenditures?

Abbott Labs (ABT) invested $2.2B in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Abbott Labs spend on research and development?

Abbott Labs (ABT) invested $2.9B in research and development during fiscal year 2025.

Does Abbott Labs buy back shares?

Yes, Abbott Labs (ABT) spent $893.0M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does Abbott Labs have outstanding?

Abbott Labs (ABT) had 1.74B shares outstanding as of fiscal year 2025.

What is Abbott Labs's current ratio?

Abbott Labs (ABT) had a current ratio of 1.58 as of fiscal year 2025, which is generally considered healthy.

What is Abbott Labs's debt-to-equity ratio?

Abbott Labs (ABT) had a debt-to-equity ratio of 0.19 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Abbott Labs's return on assets (ROA)?

Abbott Labs (ABT) had a return on assets of 7.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Abbott Labs's Altman Z-Score?

Abbott Labs (ABT) has an Altman Z-Score of 4.84, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Abbott Labs's Piotroski F-Score?

Abbott Labs (ABT) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Abbott Labs's earnings high quality?

Abbott Labs (ABT) has an earnings quality ratio of 1.47x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Abbott Labs cover its interest payments?

Abbott Labs (ABT) has an interest coverage ratio of 16.3x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Abbott Labs?

Abbott Labs (ABT) scores 56 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.